Nantahala Capital Management - Q3 2022 holdings

$1.55 Billion is the total value of Nantahala Capital Management's 120 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 105.0% .

 Value Shares↓ Weighting
IWM NewISHARES TRcall$131,936,000800,000
+100.0%
8.54%
CASH BuyPATHWARD FINANCIAL INC$43,770,000
+14.9%
1,327,968
+34.8%
2.83%
+48.2%
COST BuyCOSTCO WHSL CORP NEW$40,917,000
+19.4%
86,640
+21.2%
2.65%
+54.1%
LXFR BuyLUXFER HLDGS PLC$33,895,000
-3.7%
2,337,605
+0.4%
2.19%
+24.2%
CDXS BuyCODEXIS INC$27,294,000
-36.7%
4,504,009
+9.3%
1.77%
-18.3%
APEN BuyAPOLLO ENDOSURGERY INC$21,896,000
+61.1%
3,973,906
+6.7%
1.42%
+108.1%
QURE BuyUNIQURE NVcall$18,760,000
+25.8%
1,000,000
+25.0%
1.21%
+62.3%
IWM BuyISHARES TRrussell 2000 etf$12,430,000
+207.4%
75,370
+215.7%
0.80%
+296.1%
CNCE BuyCONCERT PHARMACEUTICALS INC$11,974,000
+71.4%
1,787,159
+7.7%
0.78%
+121.4%
AUTL BuyAUTOLUS THERAPEUTICS PLCspon ads$11,162,000
-23.3%
5,215,788
+1.4%
0.72%
-1.1%
APEN BuyAPOLLO ENDOSURGERY INCcall$11,020,000
+88.7%
2,000,000
+25.0%
0.71%
+143.3%
VMD BuyVIEMED HEALTHCARE INC$10,743,000
+16.4%
1,790,505
+4.4%
0.70%
+50.1%
BuyDARIOHEALTH CORP$10,165,000
-4.3%
2,195,373
+26.8%
0.66%
+23.5%
RH NewRHcall$9,843,00040,000
+100.0%
0.64%
PTON BuyPELOTON INTERACTIVE INCcall$9,484,000
-9.3%
1,368,600
+20.2%
0.61%
+17.2%
BuyAURA BIOSCIENCES INC$6,954,000
+43.0%
383,764
+11.8%
0.45%
+84.4%
RNG BuyRINGCENTRAL INCcl a$6,698,000
-14.6%
167,622
+11.7%
0.43%
+10.2%
NewVENTYX BIOSCIENCES INC$4,072,000116,633
+100.0%
0.26%
RMBL BuyRUMBLEON INC$4,010,000
+36.3%
236,975
+18.5%
0.26%
+75.7%
IDYA NewIDEAYA BIOSCIENCES INC$3,782,000253,480
+100.0%
0.24%
PWP BuyPERELLA WEINBERG PARTNERS$3,199,000
+9.1%
505,293
+0.5%
0.21%
+40.8%
TELA NewTELA BIO INC$2,973,000349,002
+100.0%
0.19%
BVS NewBIOVENTUS INC$2,652,000378,839
+100.0%
0.17%
TCDA NewTRICIDA INC$2,406,000229,610
+100.0%
0.16%
AAN NewTHE AARONS COMPANY INC$1,958,000201,467
+100.0%
0.13%
RZLT NewREZOLUTE INC$1,969,000718,736
+100.0%
0.13%
NewAVALO THERAPEUTICS INC$1,819,000547,814
+100.0%
0.12%
PNT NewPOINT BIOPHARMA GLOBAL INC$1,529,000197,783
+100.0%
0.10%
ANEB NewANEBULO PHARMACEUTICALS INC$1,431,000511,073
+100.0%
0.09%
AGS NewPLAYAGS INC$1,179,000222,518
+100.0%
0.08%
NewSOLENO THERAPEUTICS INC$1,009,000604,179
+100.0%
0.06%
LQDA NewLIQUIDIA CORPORATION$799,000146,792
+100.0%
0.05%
SGRP NewSPAR GROUP INC$781,000538,427
+100.0%
0.05%
SNDX NewSYNDAX PHARMACEUTICALS INCcall$721,00030,000
+100.0%
0.05%
GMTX NewGEMINI THERAPEUTICS INC$423,000257,672
+100.0%
0.03%
IDN NewINTELLICHECK INC$314,000124,594
+100.0%
0.02%
ZVO BuyZOVIO INC$281,000
-82.5%
1,961,635
+18.5%
0.02%
-77.8%
AUTL NewAUTOLUS THERAPEUTICS PLCcall$150,00070,300
+100.0%
0.01%
NewCYREN LTD$139,000141,615
+100.0%
0.01%
RFL BuyRAFAEL HLDGS INC$131,000
+263.9%
72,678
+274.0%
0.01%
+300.0%
KTRA BuyKINTARA THERAPEUTICS INC$64,000
+100.0%
594,813
+411.7%
0.00%
+100.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-11-10
Signatures

The EDGAR filing(s) were signed by:

About Nantahala Capital Management

Nantahala Capital Management is a hedge fund that was founded in 2004 by Wil Harkey. The firm is headquartered in Connecticut and has additional offices in New York and North Carolina. Nantahala Capital Management primarily invests in the technology, healthcare, and consumer sectors. The firm has a long-term investment approach and seeks to identify undervalued companies with strong growth potential.

Wil Harkey serves as the CEO and Chief Investment Officer of Nantahala Capital Management. He has over 20 years of experience in the finance industry and previously worked at Goldman Sachs and Maverick Capital. In addition to Harkey, the firm's leadership team includes COO and General Counsel, David Kozak, and CFO, Michael Kozak.

Nantahala Capital Management has a strong track record of generating positive returns for its investors. The firm's flagship fund, the Nantahala Fund, has delivered an annualized return of over 20% since its inception in 2006. The firm's success can be attributed to its disciplined investment approach and focus on long-term value creation.

Overall, Nantahala Capital Management is a well-respected hedge fund with a talented leadership team and a strong track record of performance. However, as with any investment, it is important for investors to conduct their own due diligence and carefully consider the risks before investing in the firm's funds.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ISHARES TR42Q3 202327.2%
CODEXIS INC42Q3 20233.9%
PATHWARD FINANCIAL INC35Q3 20236.3%
SCIENTIFIC GAMES CORP34Q3 20225.3%
DOVER MOTORSPORTS INC34Q3 20210.5%
GOLDEN ENTMT INC33Q3 20232.1%
QAD INC32Q3 20212.6%
SCIENTIFIC GAMES CORP31Q4 20217.7%
DOLBY LABORATORIES INC31Q4 20205.6%
LINCOLN EDL SVCS CORP31Q4 20210.7%

View Nantahala Capital Management's complete holdings history.

Latest significant ownerships (13-D/G)
Nantahala Capital Management Q3 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
AYTU BIOPHARMA, INCJune 16, 20231,086,81219.7%
Acer Therapeutics Inc.February 14, 20231,226,1917.5%
Aeglea BioTherapeutics, Inc.February 14, 20234,611,3027.5%
AKUMIN INC.February 14, 20232,206,9602.5%
ALTA EQUIPMENT GROUP INC.February 14, 20231,188,9853.7%
Apollo Endosurgery, Inc.February 14, 20234,056,6279.9%
Autolus Therapeutics plcFebruary 14, 20237,782,0184.7%
Bioventus Inc.February 14, 20233,168,5745.1%
CATALYST BIOSCIENCES, INC.February 14, 2023438,0551.4%
Drive Shack Inc.February 14, 20236,500,0007.0%

View Nantahala Capital Management's complete significant-ownership history.

Latest filings
TypeFiled
42024-03-21
42024-03-15
SC 13G2024-03-11
13F-HR/A2024-02-15
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Nantahala Capital Management's complete filings history.

Compare quarters

Export Nantahala Capital Management's holdings